NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles
- PMID: 33256910
- DOI: 10.1053/j.seminhematol.2020.10.004
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles
Abstract
Natural killer cells are an essential component of the innate immune system and play a crucial role in immunity against malignancies, without, at difference with T cells, requiring antigen priming or inducing graft-versus-host-disease. Hence, Natural Killer cells can provide a valuable source of allogeneic "off-the-shelf" adoptive therapy and mediate major antileukemia effects, without inducing potentially lethal alloreactivity. Several cell sources have been used for producing and expanding large numbers of clinical-grade natural killer cells. In this review, we will discuss the advantages and challenges of Natural Killer cell-based therapeutic approaches for hematological malignancies, also exploring different strategies to potentiate their clinical application.
Keywords: CAR; Genetic modification; HSC transplantation; Immunotherapy; KIRs; NK cell.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest The authors have no conflicting financial interests.
Similar articles
-
Advances in CAR-NK cell therapy for hematological malignancies.Front Immunol. 2024 Jun 28;15:1414264. doi: 10.3389/fimmu.2024.1414264. eCollection 2024. Front Immunol. 2024. PMID: 39007146 Free PMC article. Review.
-
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.Hematol Oncol. 2021 Feb;39(1):11-19. doi: 10.1002/hon.2802. Epub 2020 Sep 21. Hematol Oncol. 2021. PMID: 32905618 Review.
-
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018. Front Immunol. 2018. PMID: 29497427 Free PMC article. Review.
-
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.Cancer Lett. 2020 Mar 1;472:175-180. doi: 10.1016/j.canlet.2019.11.033. Epub 2019 Nov 29. Cancer Lett. 2020. PMID: 31790761 Review.
-
[Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].Bull Cancer. 2021 Oct;108(10S):S81-S91. doi: 10.1016/j.bulcan.2021.06.007. Bull Cancer. 2021. PMID: 34920811 Review. French.
Cited by
-
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.Front Oncol. 2021 Aug 6;11:720501. doi: 10.3389/fonc.2021.720501. eCollection 2021. Front Oncol. 2021. PMID: 34422667 Free PMC article. Review.
-
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.Cancers (Basel). 2021 May 20;13(10):2500. doi: 10.3390/cancers13102500. Cancers (Basel). 2021. PMID: 34065399 Free PMC article. Review.
-
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.Exp Hematol Oncol. 2024 Dec 4;13(1):118. doi: 10.1186/s40164-024-00583-7. Exp Hematol Oncol. 2024. PMID: 39633491 Free PMC article. Review.
-
Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis.Clin Exp Med. 2023 Oct;23(6):2503-2533. doi: 10.1007/s10238-022-00923-z. Epub 2022 Nov 4. Clin Exp Med. 2023. PMID: 36333526
-
Murine models to study human NK cells in human solid tumors.Front Immunol. 2023 Jun 14;14:1209237. doi: 10.3389/fimmu.2023.1209237. eCollection 2023. Front Immunol. 2023. PMID: 37388731 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources